Key result
The Micra TPS leadless pacemaker achieved a 97.8% implantation success rate, but was associated with a 9.8% major complication rate over an average 1-year follow-up.
Why the study?
What is the real-world clinical safety and efficacy of the Micra TPS leadless pacemaker in patients requiring single-chamber pacing?
Population
92 patients requiring single-chamber pacing from four different centres in the Swiss Romande region
Design
Cohort
Follow-up
average 1 year
Authors
Loading...
Real-world Swiss Micra data support safety and efficacy; leaves open need for larger prospective confirmation of long-term outcomes.
Observational (n=92)
Yes
What is the real-world clinical safety and efficacy of the Micra TPS leadless pacemaker in patients requiring single-chamber pacing?
While real-world implantation of the Micra TPS leadless pacemaker has a high success rate, it is associated with a high major complication rate (9.8%) during initial experience, highlighting the need for proper training.
Valiton et al. (2018) conducted an observational in Patients requiring single-chamber pacing (n=92). Micra TPS leadless pacemaker was evaluated on major complication rate. The Micra TPS leadless pacemaker achieved a 97.8% implantation success rate, but was associated with a 9.8% major complication rate over an average 1-year follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: